No Data
Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock
Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...
Press Release: Scilex Holding Company, Following Its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex...
Scilex Holding Sets Dividend for Preferred Stock Exchange
Scilex Holding Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate
No Data
No Data